Cork,
Did you ever take a look at Tapestry Pharma? Plan is out, has been, and it revolves around a trust for the milestone/royalty rights to TPI 287, which is currently in several trials (Phase 1 & Phase 2) for multiple indications. Liabilities are around 5 million, there are a little over 16 mm shares out, and the milestone stream would be worth 20 mm if Archer Biosciences was successful across several indications. Importantly, Archer only got the rights for N. America and Japan - if they can get passed the FDA, TPPHQ would hold the marketing rights for an approved drug for the rest of the world. It's a long shot, but there are very few following it. It's in Colorado district. FWIW.
